Biora Therapeutics (BIOR) Competitors $0.56 -0.06 (-9.89%) (As of 12/20/2024 04:34 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainSEC FilingsShort InterestTrends BIOR vs. ENSC, GNPX, BCLI, AYTU, VIRX, ADXN, BFRI, OBSV, CDT, and CEROShould you be buying Biora Therapeutics stock or one of its competitors? The main competitors of Biora Therapeutics include Ensysce Biosciences (ENSC), Genprex (GNPX), Brainstorm Cell Therapeutics (BCLI), Aytu BioPharma (AYTU), Viracta Therapeutics (VIRX), Addex Therapeutics (ADXN), Biofrontera (BFRI), ObsEva (OBSV), Conduit Pharmaceuticals (CDT), and CERo Therapeutics (CERO). These companies are all part of the "pharmaceutical products" industry. Biora Therapeutics vs. Ensysce Biosciences Genprex Brainstorm Cell Therapeutics Aytu BioPharma Viracta Therapeutics Addex Therapeutics Biofrontera ObsEva Conduit Pharmaceuticals CERo Therapeutics Ensysce Biosciences (NASDAQ:ENSC) and Biora Therapeutics (NASDAQ:BIOR) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, media sentiment, risk, institutional ownership, community ranking, earnings, profitability, valuation and analyst recommendations. Do analysts prefer ENSC or BIOR? Biora Therapeutics has a consensus price target of $23.00, indicating a potential upside of 3,970.80%. Given Biora Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Biora Therapeutics is more favorable than Ensysce Biosciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Ensysce Biosciences 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Biora Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media favor ENSC or BIOR? In the previous week, Ensysce Biosciences had 5 more articles in the media than Biora Therapeutics. MarketBeat recorded 5 mentions for Ensysce Biosciences and 0 mentions for Biora Therapeutics. Ensysce Biosciences' average media sentiment score of 0.00 equaled Biora Therapeutics'average media sentiment score. Company Overall Sentiment Ensysce Biosciences Neutral Biora Therapeutics Neutral Does the MarketBeat Community prefer ENSC or BIOR? Biora Therapeutics received 5 more outperform votes than Ensysce Biosciences when rated by MarketBeat users. Likewise, 80.00% of users gave Biora Therapeutics an outperform vote while only 60.00% of users gave Ensysce Biosciences an outperform vote. CompanyUnderperformOutperformEnsysce BiosciencesOutperform Votes360.00% Underperform Votes240.00% Biora TherapeuticsOutperform Votes880.00% Underperform Votes220.00% Do institutionals and insiders hold more shares of ENSC or BIOR? 5.6% of Ensysce Biosciences shares are owned by institutional investors. Comparatively, 43.7% of Biora Therapeutics shares are owned by institutional investors. 7.9% of Ensysce Biosciences shares are owned by insiders. Comparatively, 51.1% of Biora Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. Is ENSC or BIOR more profitable? Biora Therapeutics has a net margin of 0.00% compared to Ensysce Biosciences' net margin of -179.26%. Biora Therapeutics' return on equity of 0.00% beat Ensysce Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets Ensysce Biosciences-179.26% -292.81% -158.83% Biora Therapeutics N/A N/A -332.47% Which has higher valuation and earnings, ENSC or BIOR? Ensysce Biosciences has higher revenue and earnings than Biora Therapeutics. Ensysce Biosciences is trading at a lower price-to-earnings ratio than Biora Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEnsysce Biosciences$2.23M4.74-$10.61M-$27.44-0.30Biora Therapeutics$892K2.86-$124.11M-$13.04-0.04 Which has more risk and volatility, ENSC or BIOR? Ensysce Biosciences has a beta of 0.6, meaning that its share price is 40% less volatile than the S&P 500. Comparatively, Biora Therapeutics has a beta of 1.12, meaning that its share price is 12% more volatile than the S&P 500. SummaryBiora Therapeutics beats Ensysce Biosciences on 12 of the 17 factors compared between the two stocks. Ad Behind the MarketsWe recommended Palantir in 2021, now we’re recommending this...My research indicates there is only one investment that can meet AI's unprecedented demand for energy.Click to get the name and ticker symbol Get Biora Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for BIOR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BIOR vs. The Competition Export to ExcelMetricBiora TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.56M$6.58B$5.13B$9.07BDividend YieldN/A2.99%5.08%4.23%P/E Ratio-0.0410.5489.7417.18Price / Sales2.86195.791,116.12116.95Price / CashN/A57.1642.8237.86Price / Book-0.025.094.774.78Net Income-$124.11M$151.83M$120.15M$225.60M7 Day Performance-1.24%-2.13%-1.92%-1.23%1 Month Performance-65.34%-3.10%11.47%3.36%1 Year Performance-95.59%11.54%30.52%16.60% Biora Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BIORBiora Therapeutics1.8014 of 5 stars$0.57-9.9%$23.00+3,970.8%-95.6%$2.56M$892,000.00-0.04120Gap DownENSCEnsysce Biosciences0.0873 of 5 stars$6.90+22.8%N/A-49.1%$9.01M$2.23M-0.2010GNPXGenprex3.9233 of 5 stars$1.06-9.1%$10.00+847.9%-89.1%$8.98MN/A0.0020Gap UpBCLIBrainstorm Cell Therapeutics3.9873 of 5 stars$1.54+5.9%$30.00+1,854.4%-21.2%$8.75MN/A-0.3040Gap UpAYTUAytu BioPharma0.8898 of 5 stars$1.39-3.5%N/A-52.9%$8.55M$81M-1.17160Positive NewsVIRXViracta Therapeutics2.5296 of 5 stars$0.21+5.7%$5.00+2,233.2%-56.7%$8.52MN/A-0.1820Gap DownADXNAddex Therapeutics2.7065 of 5 stars$7.99-0.1%$30.00+275.5%+39.1%$8.47M$556,045.00-23.5330Gap DownBFRIBiofrontera1.4519 of 5 stars$1.09+2.8%$7.00+542.2%-69.7%$8.45M$35.36M-0.4770Gap DownOBSVObsEvaN/AN/AN/AN/A$7.94M$20.11M-0.1150Analyst ForecastNews CoverageCDTConduit PharmaceuticalsN/A$0.08-6.1%N/A-98.5%$7.87MN/A0.003CEROCERo TherapeuticsN/A$0.05-7.9%N/AN/A$7.85MN/A0.008 Related Companies and Tools Related Companies Ensysce Biosciences Competitors Genprex Competitors Brainstorm Cell Therapeutics Competitors Aytu BioPharma Competitors Viracta Therapeutics Competitors Addex Therapeutics Competitors Biofrontera Competitors ObsEva Competitors Conduit Pharmaceuticals Competitors CERo Therapeutics Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:BIOR) was last updated on 12/22/2024 by MarketBeat.com Staff From Our PartnersThis Crypto Is Set to Explode in DecemberIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredAI breakthrough about to upend industryEveryone is talking about AI right now. The talk has been endless ever since ChatGPT was released to the m...Porter & Company | SponsoredNvidia’s Bold Move: Tackling Tech’s $1 Trillion CrisisTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | SponsoredYour bank is lying to you.You might think you have your money in a high-yield savings account, but do you really? The national average A...MyBankTracker | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Starting with what I call Exec. Order 001. It’s a bombshell law that I believe Trump will sign within minut...Banyan Hill Publishing | SponsoredCould This Tiny Device Help You Make an Extra $30k a Year?I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more t...Brownstone Research | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowAltcoin season moves fast, and those who hesitate are left behind. The window is closing.Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Biora Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Biora Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free BIOR Stock Alerts